纳武利尤单抗治疗BRAF野生型晚期黑色素瘤五年结局
CheckMate 066研究5年分析显示,初治BRAF野生型晚期黑色素瘤患者接受纳武利尤单抗对比达卡巴嗪,5年OS率分别为39%与17%,PFS率28%与3%,ORR 42%与14%,持续缓解者生存获益显著且停药后可维持。
要点
- 纳武利尤单抗5年OS率39%、PFS率28%,均显著优于达卡巴嗪。
- 获得完全缓解者5年时88%仍存活,持续缓解与长期生存强相关。
- 5年时存活且可评估者中83%未接受后续治疗,60%已停药。
核心结论
- 5年分析证实纳武利尤单抗在所有终点上均显著优于达卡巴嗪,支持其单药长期生存获益。
- 生存与获得持续缓解强相关,且缓解可在停药后维持,即使未接受后续系统治疗。
研究设计与样本
- 多中心、双盲、III期CheckMate 066研究,418例初治不可切除III/IV期BRAF野生型黑色素瘤患者随机1:1接受纳武利尤单抗3 mg/kg每2周或达卡巴嗪1,000 mg/m2每3周。
- 主要终点为总生存(OS),次要终点包括无进展生存(PFS)、客观缓解率(ORR)和安全性。
主要发现
- 5年OS率纳武利尤单抗组39%、达卡巴嗪组17%;5年PFS率分别为28%和3%。
- ORR纳武利尤单抗组42%、达卡巴嗪组14%;5年时存活者中ORR分别为81%和39%。
- 纳武利尤单抗组42例完全缓解(20%),其中88%(37/42)在5年分析时存活。
- 75例5年时存活且可评估的纳武利尤单抗治疗者中,83%未接受后续治疗,23%仍在研究治疗中,60%已无治疗。
- 随机分配至达卡巴嗪后接受后续治疗(包括纳武利尤单抗)的37例患者,5年OS率为38%。
临床怎么用
- 对于初治BRAF野生型晚期黑色素瘤,纳武利尤单抗单药一线治疗可带来长期生存获益。
- 获得持续缓解的患者可能安全停药并维持长期生存,无需后续系统治疗。
局限性
- 随访时间中位数纳武利尤单抗组32.0个月、达卡巴嗪组10.9个月,两组随访不均衡。
- 安全性分析结果与3年报告相似,未报告新的安全性信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma. Five-year results are presented herein. PATIENTS AND METHODS: In this multicenter, double-blind, phase III study, 418 patients with previously untreated, unresectable, stage III/IV, wild-type BRAF melanoma were randomly assigned 1:1 to receive nivolumab 3 mg/kg every 2 weeks or dacarbazine 1,000 mg/m2 every 3 weeks. The primary end point was overall survival (OS), and secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety. RESULTS: Patients were followed for a minimum of 60 months from the last patient randomly assigned (median follow-up, 32.0 months for nivolumab and 10.9 months for dacarbazine). Five-year OS rates were 39% with nivolumab and 17% with dacarbazine; PFS rates were 28% and 3%, respectively. Five-year OS was 38% in patients randomly assigned to dacarbazine who had subsequent therapy, including nivolumab (n = 37). ORR was 42% with nivolumab and 14% with dacarbazine; among patients alive at 5 years, ORR was 81% and 39%, respectively. Of 42 patients treated with nivolumab who had a complete response (20%), 88% (37 of 42) were alive as of the 5-year analysis. Among 75 nivolumab-treated patients alive and evaluable at the 5-year analysis, 83% had not received subsequent therapy; 23% were still on study treatment, and 60% were treatment free. Safety analyses were similar to the 3-year report. CONCLUSION: Results from this 5-year analysis confirm the significant benefit of nivolumab over dacarbazine for all end points and add to the growing body of evidence supporting long-term survival with nivolumab mono-therapy. Survival is strongly associated with achieving a durable response, which can be maintained after treatment discontinuation, even without subsequent systemic therapies.
引用
- Robert C, Long GV, Brady B, et al. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. J Clin Oncol. 2020. PMID: 32997575. doi:10.1200/JCO.20.00995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。